Why the study?
The prevalence and role of CYP2C19 gene mutations regarding recurrent cardiovascular events in patients treated with clopidogrel remained controversial, particularly among Arab populations.
Does carrying CYP2C19 mutations increase the risk of recurrent cardiovascular events in Arab patients treated with clopidogrel for secondary prophylaxis?
Population
Arab patients previously with CVEs using clopidogrel as secondary prophylaxis
Comparison
Carriers vs non-carriers of different CYP2C19 gene variants
Design
Systematic review and meta-analysis
Authors
Loading...
CYP2C19*2/*3 carriage may confer higher recurrent CVE risk on clopidogrel in Arabs; leaves open whether genotyping or alternatives improve outcomes.
Does carrying CYP2C19 mutations increase the risk of recurrent cardiovascular events in Arab patients treated with clopidogrel for secondary prophylaxis?
In the Arab population, carriers of CYP2C19*2 and CYP2C19*3 alleles treated with clopidogrel have an approximately threefold increased risk of recurrent cardiovascular events, suggesting the need for alternative antiplatelet therapies in this subgroup.
Alkattan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: